#biosynths

this design is now up on toyhouse as a raffle! if 50 people join, I’ll add in a full ref!

Check out them all here :3

✦ We’ve now got NPC shops, roleplay threads, and currency exchange! Buy items from Cl0v3r, Bug, or 3v3 to use in the game! ✦

Taking art and trades, but any amount of Nintendo gift card works as an auto buy.

Do Biosynths know what traits are most preferred by investors/in their creating process? Do they know they have undesirable traits even if they're fully functional? Probably yes but I wanted to ask anyway

2. Can Synths get viral sicknesses? Like with the cold, or a fever, or the flu. Or anything equivalent to that?

3. Can Synths get bacterial infections or stuff that isn't viral sicknesses. Like. Appendicitis is the only thing coming to mind. Or anything equivalent to that?

4. If a synth were to get sick/the equivalent of sickness what would be the procedure for treatment?

5. What does general matienence of a biosynth entail?

I forgor

Yes. They’re incredibly susceptible to those due to the controlled environment they’re grown in.

Yes.

They would be taken out of the playroom to a “time out” room, and routinely; bathed, administered medicine and or antibiotics, and checked up on. Though they aren’t given any entertainment, only physical care.

Is there a general way the lab is laid out/how scientists may work with the biosynths?

Because I kinda want to write about Minty but also want it to like. Be canon? Or at least closely follow how you think the lab works in general?

Ok, layout, the biosynth “playroom” is a large open space with foam walls and floors. There are several structures and “hiding places” built into the room. There is also a few tables, a blackboard, and a slide.

The scientists mostly test how the synths function physically and mentally, with constant maintenance and mandatory puzzles and problems to solve.

The maintenance and testing rooms are closed off from the main room, and are usually only seen when a synth is taken into them for one reason or another.

Recent scientific advancements have shown that a lesser-known compound from the cannabis plant, cannabinol (CBN), may hold promise for treating neurological disorders such as Alzheimer’s and Parkinson’s disease. Researchers at the Salk Institute discovered that not only does CBN protect brain cells from age-related damage, but its chemically modified versions could be even more effective. These findings, detailed in the journal Redox Biology, suggest a new frontier in the treatment of traumatic brain injuries and other neurodegenerative diseases.

...

...

Previous studies indicated that CBN could help preserve mitochondrial function in brain cells, an essential factor for cell survival and energy production. Mitochondrial dysfunction is a common feature in several neurodegenerative diseases, often leading to cell death. By focusing on CBN and its derivatives, researchers aimed to develop new pharmacological strategies to prevent or mitigate the cellular mechanisms that lead to neurodegeneration.

...

Once the key protective fragments of CBN were identified, the team synthesized four novel analogs. These derivatives were designed to enhance the neuroprotective attributes of the original CBN molecule, with modifications intended to increase their ability to penetrate the brain, act faster, and provide stronger effects in protecting against cell death.

“Not only does CBN have neuroprotective properties, but its derivatives have the potential to become novel therapeutics for various neurological disorders,” said Research Professor Pamela Maher, the senior author of the study. “We were able to pinpoint the active groups in CBN that are doing that neuroprotection, then improve them to create derivative compounds that have greater neuroprotective ability and drug-like efficacy.”

...

CP1 showed superior performance in the fruit fly model of traumatic brain injury, significantly increasing survival rates compared to flies that did not receive treatment. This result suggests that CP1 could potentially be developed into a therapeutic agent capable of offering protection against the acute impacts of brain injuries.

“Our findings help demonstrate the therapeutic potential of CBN, as well as the scientific opportunity we have to replicate and refine its drug-like properties,” Maher said. “Could we one day give this CBN analog to football players the day before a big game, or to car accident survivors as they arrive in the hospital? We’re excited to see how effective these compounds might be in protecting the brain from further damage.”